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Abstract
Background: Sixty mutations of claudin 16 coding gene have been reported in familial hypomagnesemia with
hypercalciuria and nephrocalcinosis (FHHNC) patients. Recent investigations revealed that a highly conserved
glycine-leucine-tryptophan (115G-L-W117) motif in the first extracellular segment (ESC1) of claudin 16 might be
essential for stabilization of the appropriately folded ECS1 structure and conservation of normal claudin 16 function.
However, neither missense nor nonsense mutation has ever been described in this motif. Our study aimed at identifying
mutations in a Chinese patient with FHHNC and exploring the association between genotype and phenotype.
Case presentation: A 33-year-old female presented with 4 years history of recurrent acute pyelonephritis without other
notable past medical history. Her healthy parents, who aged 56 and 53 respectively, were second cousins, and her only
sibling died from renal failure without definite cause at age 25. Renal ultrasound imaging demonstrated atrophic kidneys
and bilateral nephrocalcinosis. The laboratory workup revealed impaired renal function (Stage CKD IV), hypocalcemia and
mild hypomagnesemia, accompanied with marked renal loss of magnesium and hypercalciuria. During the follow-up,
treatment with calcitriol and calcium but not with magnesium was difficult to achieve normal serum calcium
levels, whereas her serum magnesium concentration fluctuated within normal ranges. In the end, the patient
unavoidably reached ESRD at 36 years old. The clinical features and family history suggested the diagnosis of
FHHNC. To make a definite diagnosis, we use whole-exome sequencing to identify the disease-causing mutations
and Sanger sequencing to confirm the mutation co-segregation in the family. As a result, a novel homozygous
mutation (c.346C > G, p.Leu116Val) in 115G-L-W117 motif of claudin 16 was identified. Her parents, grandmother
and one of her cousins carried heterozygous p.Leu116Val, whereas 200 unrelated controls did not carry this mutation.
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Conclusions: We described a delayed diagnosis patient with FHHNC in the Chinese population and identified a novel
missense mutation in the highly conserved 115G-L-W117 motif of claudin 16 for the first time. According to the reported
data and the information deduced from 3D modeling, we speculate that this mutation probably reserve partial residual
function which might be related to the slight phenotype of the patient.
Keywords: Familial hypomagnesaemia with Hypercalciuria and Nephrocalcinosis, Claudin 16, Mutation, Highly
conserved motif
Background
Familial hypomagnesemia with hypercalciuria and nephro-
calcinosis (FHHNC) is a rare autosomal-recessive renal
tubular disorder characterized by excessive urinary losses
of magnesium and calcium, bilateral nephrocalcinosis and
progressive chronic renal failure [1]. This disease is caused
by mutations in the tight junction (TJ) proteins,
claudin-16 and -19, which are encoded by the CLDN16
(OMIM #248250) or CLDN19 (OMIM #248190) genes re-
spectively [2, 3]. These two proteins are expressed in the
thick ascending limb (TAL) of Henle’s loop and are in-
volved in the paracellular reabsorption of calcium and
magnesium [4]. There is no evident difference in renal
phenotypes between patients with mutations in CLDN16
and CLDN19, however, severe ocular involvement has
been described in CLDN19 patients that might be attrib-
uted to extra-renal expression of claudin-19 in nervous
system and retina [3].
So far, 60 different mutations of the CLDN16 gene
have been described, including 39 missense mutations, 7
nonsense mutations, 6 splice site mutations, 4 small de-
letions and 4 other types of mutations (Additional file 1:
Figure S1) [2, 5–25]. These mutations spread across the
five exons of the CLDN16 gene, and most missense mu-
tations are located in or near the four transmembrane
domains, especially in the two extracellular segments
(ECSs) and in the carboxy-terminal cytoplasmic region
(Additional file 1: Figure S1). The majority of previously
studied patients with FHHNC came from European,
Middle Eastern and North African countries, and only a
few had been reported in USA, East Asia or South Asia
[7]. So far only a homozygous CLDN16 indel mutation
associated with FHHNC has been reported in two pa-
tients from a Chinese family [22].
Research studies using mouse and cell models have
generated significant advances in the understanding of
the pathophysiology of FHHNC. The determination of
the first crystal structure of a mammalian claudin (clau-
din-15) would not only provide structural information
on this family of TJ proteins but also help to further
understand the molecular mechanisms of this disease
[25]. In the first extracellular segment (ESC1), a highly
conserved glycine-leucine-tryptophan (115G-L-W117)
motif among all members of the claudin family has been
found probably helpful for stabilization of the appropri-
ately folded ECS1 structure [26]. However, no missense
mutation was reported in these three amino acid
residues thus far. Here, we reported a Chinese FHHNC
family associated with a novel missense mutation of the
highly conserved Leucine residue 116 in the
115G-L-W117 motif.
Case presentation
In Mar 2013, a 33-year-old female came to the nephrology
department because of 4 years of recurrent acute pyelo-
nephritis. She had no other notable past medical history
including polyuria, polydipsia, muscular cramps, carpope-
dal spasms or generalized seizures, and did not take any
regular medication. Her parents, who aged 56 and 53 re-
spectively, were second cousins and denied any remark-
able medical history. Her only sibling died from renal
failure without definite cause at age 25. The pedigree of
the family is shown in Fig. 1. Physical examination re-
vealed that her height was 160 cm (The average height of
Chinese adult females at corresponding age is 159 cm.)
and her weight was 55 kg with a BMI of 21.48 kg/m2.
Laboratory workup revealed impaired renal function (SCr
250 μmol/L, EPI-eGFR = 21.1 ml/min/1.73m2), hypocalce-
mia (1.42 mmol/l, normal range 2.11–2.52), and normal
serum parathyroid hormone levels (65.59 pg/ml) in the
context of normal 25OH-Vitamin D levels (26 ng/ml, ref-
erence range 20.0–32.0) (Table 1). Her serum magnesium
level was slightly low (0.60 mmol/l, reference range 0.65–
1.20), and 24-h urinary calcium was 3.9 mmol/1.73m2
(normal range 2.5–5.5) in the setting of decreased renal
function. Distal renal tubular acidosis was excluded since
she had normal urine acidification function (pH < 5.3) in
the setting of nearly normal serum bicarbonate level
(HCO3
− 22 mmol/l). Renal ultrasound imaging demon-
strated bilateral nephrocalcinosis and parenchymal renal
calculi, with the right kidney length 9.5 cm and the left
9.4 cm. Ophthalmologic examination was normal. During
the subsequent 3 years of follow-up, she had undergone
six attacks of acute UPI. In the interictal phase of infec-
tions, she had accepted four times of biochemical assess-
ment (Table 1). Repeated examinations in the follow-up
revealed marked renal loss of magnesium (fractional
excretion 42.7 ± 7.4%, normal range less than 5%) and
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Fig. 1 Pedigree of the Chinese family with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. □, male; ○, female; ↗, proband
Table 1 Laboratory findings of the proband during the hospitalization and 3-year follow-up
Items First Admission First follow-up Second follow-up Third follow-up Fourth follow-up Normal Range
Date Mar, 2013 Mar, 2014 Aug, 2014 Feb, 2016 Jun, 2016
Age (yrs) 33 34 34 36 36
SCr (μmol/L) 250 270 306 537 647 31–132
eGFRa (ml/min/1.73m2) 21.1 19.1 16.4 8.2 6.5 > 90
SK (mmol/L) 4.2 4.3 4.4 4.9 4.7 3.5–5.5
SMg (mmol/L) 0.65 NA 0.70 0.99 0.91 0.65–1.20
SCa (mmol/L) 1.42 1.63 1.68 1.81 1.58 2.11–2.52
SP (mmol/L) 1.7 2.0 1.5 2.0 2.1 0.8–1.6
HCO3 (mmol/L) 22.0 21.0 20.0 23.7 21.7 23.0–31.0
ALB (g/L) 37.2 NA 47.8 39.6 46.5 35.0–55.0
ALP (U/L) 40.8 NA NA NA 60.9 35–125
PTH (pg/ml) 65.6 74.5 75.6 73.8 94.5 15.0–65.0
UpH 5.0 5.0 NA NA NA
24 h-UCa (mmol/1.73m2) 3.9 4.3 3.8 2.1 2.0 2.5–5.5
UCa/Cr (mol/mol) NA 0.61 0.57 0.46 0.44 0.15–0.33
24 h-UMg (mmol/1.73m2) NA 7.1 7.0 3.9 4.2
FEMgb NA 38.5% 43.7% 35.9% 52.7% < 5.0%
25OH-VitD NA NA NA NA 22.4 20.0—32.0
UProtein 1.07 g/24 h + NA NA + Negative
eGFR Estimated glomerular filtration rate, S Serum, ALB Albumin, ALP Alkaline phosphate, PTH Parathyroid hormone, U Urine, NA Not available. a, Calculated by
CKD-EPI formula; b, Calculated by the following formula: UMg × SCr/(0.7 × SMg × UCr) × 100%
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hypercalciuria (urinary calcium/creatine 0.52 ± 0.08 mol/
mol, normal range 0.15–0.33). Treatment with calcitriol
and calcium but not with magnesium was difficult to
achieve a considerable effect on her serum calcium,
whereas her serum magnesium concentration fluctuated
within the normal range (0.70–0.91 mmol/l) under the
circumstances of renal failure. Plain abdominal radiograph
and abdominal CT scanning, which were performed in
Mar 2014 and Feb 2016 respectively, demonstrated grad-
ually aggravated nephrocalcinosis and atrophy of renal
parenchyma (Fig. 2). In the end, the patient unavoidably
reached ESRD at the age of 36. The gradient of GFR de-
cline was calculated to be 4.3 ml/min per 1.73 m2/yr.
during the follow up, whereas the gradient of GFR decline
was about 2.1 ml/min per 1.73 m2/yr. 3 years before the
period of follow up, and the approved global slope of de-
cline was 2.5 ml/min per 1.73 m2/yr.
Nephrocalcinosis associated with end-stage renal
failure is usually seen in three genetic diseases: primary
hyperoxaluria, Dent’s disease, and FHHNC. Meanwhile,
hypercalciuric hypomagnesemia is mainly seen in
FHHNC, autosomal dominant hypocalcemia with hyper-
calciuria (CASR gain-of-function), or Bartter syndrome
type III. Although the patient’s family history, hypocalce-
mia, and hypomagnesemia suggested FHHNC, we per-
formed whole-exome sequencing (WES) to exclude the
possibilities of comorbid diseases or potential mutations
of other genes that could affect the renal reabsorption of
calcium and magnesium. All the family members and
healthy controls gave informed consent. The study
protocol was approved by the Ethics Committee on
Human Studies at the Affiliated Hospital of Qingdao
University. As a result, a homozygous cytosine-to-guan-
ine substitution at position 346 of the open reading
frame (c.346C > G) in exon 2 of CLDN16 gene was
identified by WES. This single nucleotide alteration led
to a single amino acid substitution from leucine to valine
at amino acid position 116 of claudin 16 (p.Leu116Val;
Of note, there is still controversy about the physiological
use of the initiation codon. The numbering of the muta-
tion regarded to the second ATG would be p.Leu46Val.)
(Fig. 3). Sanger sequencing validation of all family mem-
bers revealed that four of her unaffected members
including her parents, grandmother and one of her
cousins carried heterozygous p.Leu116Val mutation in
CLDN16, whereas other family members and 200 unre-
lated controls from the same ethnic background
(Chinese Han population) did not carry this mutation.
This novel variant was highly conserved among 8 differ-
ent species (Human, Rat, Frog, Chimpanzee, Eagle,
Horse, Turtle & Cattle) (Additional file 2: Figure S2) and
among all 27 Human Claudins family members, and
never been reported in 1000G, ExAC, or EVS. All four
in silico prediction tools (SIFT, PolyPhen2, Mutation
taster, and PROVEAN) showed a possibility of
disease-causing for FHHNC. In addition, analysis by
HSF 3.0 (http://www.umd.be/HSF3/HSF.shtml) software
showed that no significant alteration of splicing regula-
tory elements occur after mutation.
A three-dimensional (3D) model of Claudin 16 was
built using the homology modeling approach imple-
mented in the modeler-9 package. The result showed
that the conserved W-L-W motif of the Claudin family
(Trp99, Leu116, and Trp117 in Claudin 16) was embed-
ded in a crevice formed by the top of the four-helix
bundle. Leu116 and Trp117 protrude from the tip of
the β2-β3 loop and were likely associated with Trp99 to
serve as a “hydrophobic anchor” for the β-sheet do-
main. The L116 V mutation was predicted to abolish
such interaction, resulting in a displacement of the
Fig. 2 Imaging of renal tract in the proband. a. Plain abdominal radiograph showing bilateral nephrocalcinosis, aged 34 years. b. CT scan showing
bilateral nephrocalcinosis, aged 34 years. c. CT scan showing bilateral nephrocalcinosis, aged 36 years. d. Plain abdominal radiograph showing bilateral
nephrocalcinosis, aged 36 years
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β-sheet domain from the four-helix bundle domain of
Claudin 16 (Fig. 4).
Discussion and conclusions
Since the first clinical description of FHHNC by
Michelis et al. in 1972 [27], only about 120 cases were
reported worldwide. In the Chinese population, only two
genetically confirmed FHHNC cases from a consanguin-
eous family were described so far, and a homozygous
indel mutation (c.574_589delinsTACCGGTCTGGCTG-
GACTAGCAA) was found [22]. In this paper, we
described the phenotype of a FHHNC patient from
another family and find a novel missense mutation
(c.346C > G, p.Leu116Val) by WES.
The pathogenesis of chronic kidney disease (CKD) in
FHHNC remains unclear. In the period of 3 years of
follow-up, the patient exhibited a faster decline in renal
function compared with the early phase of before
33 years of age, this may be related to the renal intersti-
tial nephritis and accelerated renal parenchyma damage
due to UPI, and the inflammation caused by the infec-
tion may further promote calcium deposition in the kid-
ney [28]. Therefore, the nephrocalcinosis and infection
played a significant negative impact on the chronic
kidney disease (CKD). However, apparently, claudin-16
might actively involve the impairment of renal function
through still unclear mechanisms, since not all inherited
tubulopathies characterized by nephrocalcinosis do uni-
formly lead to ESRD. The insidious course of the
patient’s sister suggested a potential role of claudin 16 to
some extent. Recently, it is speculated that Claudin 16
not only is the major constituent of TJ and forms
strands that mediate cell adhesion and function as para-
cellular barriers in the TAL of Henle’s loop, but also may
be involved in the regulation of cell growth, prolifera-
tion, differentiation, and dedifferentiation [29, 30]. The
defective claudin-16 probably leads to the disruption of
tubular TJ complex, and subsequent alterations of cell
polarity and an induction of tubular dysplasia, and re-
sultant transforming of tubular epithelial cells into new
fibroblasts that was well acknowledged as a progress of
renal fibrosis and renal failure.
Konrad et al. had established a phenotype-genotype
correlation regarding renal failure progression in
FHHNC patients with CLDN16 mutations [17]. They
had studied a cohort of 71 affected individuals and
found that patients with complete loss of function
mutations in both alleles exhibit a younger age at the
Fig. 3 The novel missense mutation (c.346C > G, p.Leu116Val) identified in the patient with familial hypomagnesemia with hypercalciuria and
nephrocalcinosis. a. Wild type; b. Heterozygous mutation of p.Leu116Val; c. Homozygous mutation of p.Leu116Val
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presentation of FHHNC symptoms (2.2 versus 5.6 yrs)
and a more rapid decline in renal function (7.3 versus
2.9 ml/min per 1.72 m2/yr) when compared with those
bearing at least one mutation reserving partial function
[17]. These data suggested that the presence of at least
one CLDN16 allele with partial function was enough to
predict a relatively milder clinical phenotype. Accord-
ingly, the proband with a mild phenotype reflected that
the mutation p.Leu116Val probably retained a significant
residual claudin-16 function.
Recently Suzuki et al. reported the first crystal struc-
ture of a mammalian claudin (claudin-15), providing
structural information on this family of TJ proteins [26].
Claudin 16 consists of four transmembrane domains
(TM1–4), two extracellular segments (ECS1 and ECS2),
amino- and carboxy-terminal cytoplasmic tails and a
short cytoplasmic loop. The TM segments form a typical
left-handed four-helix bundle, and large portions of the
two ECSs form a prominent β-sheet structure [26]. The
β-sheet domain extends from the membrane surface and
comprises five β strands (β1 to β5), four contributed by
ECS1 and one by ECS2. At the end of ECS1, the β4
strand connects to a short extracellular helix (ECH) that
connects to TM2 after a sharp bend. Of note, ECS1 con-
tains a conserved 115G-L-W117 motif that seems to con-
tribute to the stabilization of the appropriately folded
ECS1 structure [26]. According to the 3D model,
Leu116 and Trp117 protrude from the tip of the β2-β3
loop and appear to be close to the extracellular mem-
brane surface, serving as an “anchor” for the β-sheet do-
main. In addition, Leu116, via its main-chain carbonyl
groups, forms hydrogen bonds with the guanidinium
group of Arg149, further stabilizing the β-sheet domain
and the following ECH region [26]. Therefore, we pro-
posed that mutation p.Leu116Val may lead to instability
of the extracellular domains of the membrane protein of
claudin 16, and accordingly the reduction of the intrinsic
activity. Most noteworthy, the investigation regarding
claudin 1 demonstrated that alanine substitution of the
residue Leu50 (corresponding to Leu116 of claudin 16)
did not impair claudin-1 cell surface expression or
lateral protein interactions within the plasma membrane,
however, on the contrary, disturb the formation of
cell-cell contacts and hepatitis C virus entry [31]. Com-
bining all the data from above-mentioned investigations
regarding claudin 1, and genotype-phenotype associa-
tions of FHHNC, it was reasonable to presume that
mutant claudin 16 with p.Leu116Val, although with a
significant loss of function compared with wild-type
claudin-16, probably could properly target to the cell
membrane and TJ, and still retain a significant residual
function. However, the exact molecular pathogenetic
Fig. 4 Comparison between Wild-Type Claudin 16 (cyan ribbons) and L116 V mutant (green ribbons). The conserved W/LW motif of the Claudin
family (Trp99, Leu116, and Trp117 in Claudin 16) is shown as sticks
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mechanisms of the mutation need further in vitro
expression study to confirm.
There are three possible reasons why proband have
not been diagnosed in the past 4 years. Firstly, although
the proband had nephrocalcinosis, noticeable hypomag-
nesemia was absent. She had no other notable past med-
ical history including polyuria, polydipsia, muscular
cramps, carpopedal spasms or generalized seizures, and
did not take any regular medication. It is easy to under-
stand that patients without typical clinical manifestations
were not easily diagnosed. Secondly, only two cases were
reported in China, and it is common that Clinicians
lacked understanding of the disease. Lastly, the proband
had not been evaluated after the death of her sibling
because of kidney failure of unknown origin.
Distal renal tubular acidosis (dRTA) is common in
FHHNC patients. Weber S et al. found that 17 in 20
patients with CLDN16 mutations presented with incom-
plete dRTA [6]. The distal acidification defect was due
both to defective ammonia transfer to the distal nephron
and to defective hydrogen ion secretion at the level of
the medullary collecting duct [32]. Since this defect is
probably secondary to the medullary interstitial ne-
phropathy caused by FHHNC, dRTA would not inevit-
ably appear in some patients, just like our patient.
Rickets and/or pathological fractures, probably caused
by chronic hypocalcemia, metabolic acidosis, secondary
hyperparathyroidism, were not commonly reported in
FHHNC [20] and were absent in this patient. Moreover,
noticeable hypomagnesemia was also absent in our pa-
tient, which possibly related to the decreased GFR lead-
ing to lower filtration of magnesium. In the background
of renal insufficiency, fractional excretion of magnesium
might be especially helpful for timely diagnosis.
In summary, we identified a novel missense mutation
(c.346C > G, p.Leu116Val) in the highly conserved
115G-L-W117 motif of claudin 16 for the first time. Based
on previous investigations and 3D modeling of claudin
16, this mutation was proposed to lead to instability of
the ECS1 domains, but probably preserves significant re-
sidual function, which could be further proved by the
mild clinical phenotype resulted from this novel muta-
tion seen in our patient. Meanwhile, the exploration of
the molecular pathogenic mechanisms of this missense
mutation will particularly be interesting.
Additional files
Additional file 1: Figure S1. Schematic representation of the claudin-16
protein and positioning of reported missense/nonsense mutations in CLDN16.
The underlined is the novel mutation p.L116 V identified in this study. On the
basis of the results of mutation analysis and sequence comparisons, the
claudin 16 protein seems to be shorter than reported previously (the 70
amino-terminal amino acids that are presumably lacking are depicted
in gray). (PNG 21796 kb)
Additional file 2: Figure S2. The result of sequence alignment on 8
species of Claudin 16 homologous proteins. Black arrows are pointing to
leucine at position 116. (TIF 2004 kb)
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